Clinical profile of systemic lupus erythematosus among children less than 12 years

Andy, Senthil Kumar; Kandasamy, Elayaraja

doi:10.18203/2349-3291.ijcp20180458

Cited by 5 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 The study by Srivastava et al showed that patients with class III and IV lupus nephritis had worse outcome (ESRD/death) compared to those with class II and V. 12 Another study from South India by Andy SK et al showed proteinuria (> 0.5 g/day) in 40% of the study subjects and the most common histopathological type found on renal biopsy was class IV (42.8%) followed by class III (21.4%) and class V (21.4%). 13 Among children with SLE, 20-75% will develop LN, with 18-50% progressing to ESRD. 14 However, in our study none of the children with renal involvement progressed to ESRD.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Immunological Spectrum of Systemic Lupus Erythematosus in Children

Kini

Bhat

Thunga

et al. 2020

J. Nepal Paedtr. Soc.

View full text Add to dashboard Cite

Introduction: Systemic Lupus Erythematosus (SLE) is an auto immune disorder affecting mainly adolescent females and young women of reproductive age. The disease is characterised by widespread inflammation of blood vessels and connective tissues due to the presence of anti-nuclear antibodies (ANA). There are limited number of studies from South India on paediatric lupus. Our objectives were to study the clinical and immunological features of childhood SLE along with treatment modalities and its outcome at the end of one year follow up. The correlation between various auto-antibodies and systemic involvement was also assessed. Methods: This was a retrospective observational study carried out in paediatric unit at a tertiary care centre in South India. Data was obtained through patient’s medical records. From April 2003 to April 2019, 32 children were diagnosed to have SLE as per the American college of Rheumatology 1997 criteria. Results: The study population included 32 children fulfilling the criteria. Female to male ratio was 4.3:1. The mean age at diagnosis was 11.52 years. The most common clinical manifestations were renal (87.5%) followed by haematological (81.3%), musculoskeletal (59.4%), mucocutaneous (53.1%) and nervous system (31.3%) involvement. All patients were positive for anti-nuclear antibodies. Anti-double stranded DNA (78.1%) was the most common auto-antibody profile followed by anti-ribosomal p protein (37.5%) and anti-nucleosome antibody (37.5%). During the follow up, 13 (40.6%) children attained complete remission, 10 (31.2%) went into partial remission and nine (28.1%) had persisting active disease. Conclusion: The clinical spectrum and outcome of paediatric SLE depends upon the age of presentation and number of organ systems involved at the time of diagnosis. Our study throws light on various aspects of SLE in children from developing countries like India.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Immunological Spectrum of Systemic Lupus Erythematosus in Children

Kini

Bhat

Thunga

et al. 2020

J. Nepal Paedtr. Soc.

View full text Add to dashboard Cite

show abstract

“…22 Meanwhile, the most common histopathological renal biopsy class was class IV (42.8%) in the study by Andy and Kandasamy. 23 We found that the SLEDAI score with a range of 2-22 with a mean of 9.43±4.52. The Turkish and Canadian (23.8 ± 11.6).…”

Section: Discussionmentioning

confidence: 68%

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Teama¹,

El-Mohamdy²,

Mahmoud³

et al. 2021

OARRR

View full text Add to dashboard Cite

This study was conducted to estimate the frequency of anti-nuclear antibodies (ANAs), anti-dsDNA, and anti-extractable nuclear antigen (ENA) antibodies in juvenile systemic lupus erythematosus (JSLE) patients and their association with different clinical manifestations and disease activity. Patients and Methods: A cross-sectional study that includes 100 JSLE patients from Ain Shams University Hospital was conducted. All subjects underwent history taking, clinical examination, assessment of disease activity based on the SLE disease activity index (SLEDAI), laboratory investigations, and tests for autoantibodies, namely ANA, anti-dsDNA, and anti-ENA antibodies, including anti-Ro (SSA), anti-La (SSB), anti-Smith (Sm), and anti-U1-ribonucleoprotein (U1-RNP). Results: The most common clinical features were polyarthralgia (71%), haematological manifestations (65%), malar rash (54%), and nephritis (51%), respectively. All patients had positive ANA (100%), while anti-dsDNA frequency was 83%. The most common anti-ENA antibodies were anti-RNP (41%), anti-Sm (31%), anti-SSA (27%), and anti-SSB (20%), respectively. Anti-RNP had a clinical association with oral ulcer, Raynaud' phenomena, haematological, neuropsychiatric and thromboembolic manifestations. Meanwhile, anti-Sm had a significant association with serositis, mucocutaneous, constitutional, and neuropsychiatric manifestations. Anti-SSA was associated with mucocutaneous, musculoskeletal, Raynaud' phenomena, renal, haematological and cardiac manifestations, while anti-SSB was significantly associated with malar rash, serositis, thromboembolic, musculoskeletal, and neuropsychiatric manifestations. Concerning SLEADI score, anti-dsDNA antibody was significantly associated with moderate disease activity score (p=0.032) while anti-SSA significantly associated with high disease activity (p=0.045). Both anti-SSB and anti-Sm were significantly associated with both moderate and high disease activities, meanwhile anti-U1-RNP was associated with moderate disease activity (p=0.014). Conclusion:Anti-dsDNA and anti-ENAs antibodies were frequently found in JSLE patients (83%, 63%), respectively. They were significantly associated with variable clinical manifestations and could be used as predictors for assessment of disease activity.

show abstract

“…MĐHĐ giảm dần sau điều trị bệnh có đáp ứng. Andy đánh giá một nhóm bệnh nhi thấy điểm SLEDAI trung bình lúc bắt đầu bị bệnh là 12.54±4.94, sau 1 năm SLEDAI giảm hơn là 10.02±4.47, P=0.32 [6]. Các nghiên cứu có tần suất các dấu ấn miễn dịch khác nhau có thể do khác biệt đặc điểm lâm sàng các nhóm bệnh nhân, ở thời điểm tiến triển bệnh Lupus khác nhau.…”

Section: Biến đổI Các Dấu ấN Miễn Dịch Và đIểm Sledai Theo Thời Gianunclassified

Liên quan giữa các kháng thể kháng dsDNA, nucleosome và C1q với mức độ hoạt động bệnh Lupus ban đỏ hệ thống trẻ em

Hương¹,

Huong²,

Thị³

2019

JPRP

View full text Add to dashboard Cite

Đặt vấn đề: Bên cạnh kháng thể kháng dsDNA (Anti-dsDNA), kháng thể kháng nucleosome (AnuA) và C1q (AC1qA) là những kháng thể mới đang được nghiên cứu với hy vọng tìm được các dấu ấn miễn dịch hiệu quả trong đánh giá mức độ hoạt động bệnh Lupus.Mục tiêu: Đánh giá mối liên quan giữa Anti-dsDNA, AnuA và AC1qA với mức độ hoạt động bệnh Lupus ở trẻ em theo thang điểm SLEDAI.Phương pháp: Nghiên cứu mô tả tiến cứu một loạt ca bệnh.125 bệnh nhi Lupus được đánh giá mức độ hoạt động bệnh theo thang điểm SLEDAI. Định lượng Anti dsDNA, AnuA, AC1qA bằng phương pháp ELISA.Kết quả: Tỷ lệ dương tính cao của Anti-dsDNA 82,4%, AnuA 91,2%, AC1qA 67,2%, C3 và C4 giảm 90,4%. Anti-dsDNA, AnuA, aC1qA có liên quan với điểm SLEDAI có ý nghĩa thống kê ở các mức độ khác nhauKết luận: Anti-dsDNA, AnuA và AC1qA liên quan với điểm SLEDAI và có thể sử dụng trong theo dõi mức độ hoạt động bệnh Lupus.

show abstract

Clinical profile of systemic lupus erythematosus among children less than 12 years

Cited by 5 publications

References 6 publications

Clinical and Immunological Spectrum of Systemic Lupus Erythematosus in Children

Clinical and Immunological Spectrum of Systemic Lupus Erythematosus in Children

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Liên quan giữa các kháng thể kháng dsDNA, nucleosome và C1q với mức độ hoạt động bệnh Lupus ban đỏ hệ thống trẻ em

Contact Info

Product

Resources

About